Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer-Reference-Cited by-同舟云学术

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Published:2023-06 Issue:06 Volume:83 Page:653-663
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Hartkopf Andreas D.¹,Fehm Tanja N.²,Welslau Manfred³,Müller Volkmar⁴,Schütz Florian⁵,Fasching Peter A.⁶,Janni Wolfgang¹,Witzel Isabell⁷,Thomssen Christoph⁸,Beierlein Milena⁶,Belleville Erik⁹,Untch Michael¹⁰,Thill Marc¹¹,Tesch Hans¹²,Ditsch Nina¹³,Lux Michael P.¹⁴,Aktas Bahriye¹⁵,Banys-Paluchowski Maggie¹⁶,Kolberg-Liedtke Cornelia¹⁷,Wöckel Achim¹⁸,Kolberg Hans-Christian¹⁹,Harbeck Nadia²⁰,Stickeler Elmar²¹,Bartsch Rupert²²,Schneeweiss Andreas²³,Ettl Johannes²⁴,Würstlein Rachel²⁰,Krug David²⁵,Taran Florin-Andrei²⁶,Lüftner Diana²⁷

Affiliation:

1. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

2. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

3. Onkologie Aschaffenburg, Aschaffenburg, Germany

4. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

5. Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany

6. Erlangen University Hospital, Department of Gynecology and Obstetrics; Comprehensive Cancer Center Erlangen EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

7. Klinik für Gynäkologie, Universitätsspital Zürich, Zürich, Switzerland

8. Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

9. ClinSol GmbH & Co KG, Würzburg, Germany

10. Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany

11. Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany

12. Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany

13. Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany

14. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany

15. Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany

16. Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

17. Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany

18. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

19. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

20. Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany

21. Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany

22. Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

23. National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

24. Klinik für Frauenheilkunde und Gynäkologie, Klinikum Kempten, Klinikverbund Allgäu, Kempten, Germany

25. Klinik für Strahlentherapie, Universitätsklinkum Schleswig-Holstein, Campus Kiel, Kiel, Germany

26. Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany

27. Medical University of Brandenburg Theodor-Fontane, Immanuel Hospital Märkische Schweiz, Buckow, Germany

Abstract

AbstractWith abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study.Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan.In this review paper, we summarize and place in context the latest developments over the past months.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2074-0551.pdf

Reference87 articles.

1. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival;JMN Lopes Cardozo;J Clin Oncol,2023

2. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci;AA DeVries;J Natl Cancer Inst,2022

3. Genetic insights into biological mechanisms governing human ovarian ageing;KS Ruth;Nature,2021

4. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk;PM Kapoor;J Natl Cancer Inst,2021

5. Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women;L Dorling;N Engl J Med,2021